M2 EQUITYBITES-June 4, 2019-Genentech reveals results of two phase III Xolair
M2 PHARMA-June 4, 2019-Genentech reveals results of two phase III Xolair
, an injectable biologic medicine designed to target and block immunoglobulin E (IgE), was shown to be well tolerated and the safety profile was consistent with that observed in previous studies in people with moderate to severe allergic asthma and chronic idiopathic urticaria.
Genentech, a member of the Roche Group, announced positive topline data from two Phase III multicenter studies evaluating Xolair
for the treatment of adults with chronic rhinosinusitis with nasal polyps, or CRSwNP, who have not adequately responded to intranasal corticosteroids.
Like omalizumab (Xolair
), approved in the United States and Europe for treatment of CSU, ligelizumab is a humanized anti-IgE monoclonal antibody.
drug delivery, 150mg inj sol 1x1ml, 1x1ml unit, 3 500
According to IQVIA sales data for the 12-month period ended May 2018, annual sales of Xolair
were approximately $2.0 billion in the U.S.
(omalizumab; Novartis/Roche): For which patient population do Promoters and Detractors say Xolair
is most effective?
This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair
(omalizumab), and is a consequence of new market entrants and rising disease prevalence.
Eastern is as a consultant to Genentech, which markets omalizumab as Xolair
EXPECT (the Xolair
Pregnancy Registry) is an ongoing, prospective observational study of pregnant women who received at least 1 dose of omalizumab within 2 months of conception or during their pregnancies.
A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair
(omalizumab) in peanut allergy.